JPH08208423A - Dermal preparation for external use - Google Patents

Dermal preparation for external use

Info

Publication number
JPH08208423A
JPH08208423A JP3933895A JP3933895A JPH08208423A JP H08208423 A JPH08208423 A JP H08208423A JP 3933895 A JP3933895 A JP 3933895A JP 3933895 A JP3933895 A JP 3933895A JP H08208423 A JPH08208423 A JP H08208423A
Authority
JP
Japan
Prior art keywords
skin
water
preparation
lipid bilayer
symptoms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP3933895A
Other languages
Japanese (ja)
Inventor
Tatsuro Yamamura
達郎 山村
Yukari Yabaneta
ゆかり 矢羽田
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Noevir Co Ltd
Original Assignee
Noevir Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Noevir Co Ltd filed Critical Noevir Co Ltd
Priority to JP3933895A priority Critical patent/JPH08208423A/en
Publication of JPH08208423A publication Critical patent/JPH08208423A/en
Pending legal-status Critical Current

Links

Landscapes

  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)

Abstract

PURPOSE: To obtain a dermal preparation for external use, capable of reproducing the water holding functions possessed by the skin horny layer on the skin, effectively supplementing water to the skin or preventing water from evaporating from the skin and effective in improving skin symptoms, treating dermatopathy and prevention thereof. CONSTITUTION: This skin preparation for external use is obtained by preparing a lipid bimolecular membrane using a glycerophospholipid, a sphingophospholipid, a glyceroglycolipid, a sphingoglycolipid, etc., adding and compounding one or more selected from proline, leucine and isoleucine and one or more water-soluble polymers therewith, forming the resultant compounded lipid bimolecular membrane into a multilamellar layer (lamellar) structure such as a liposome, adding and dispersing the prepared lamellar structure in a base used in a preparation for external use. When the preparation is applied to the skin, the compounded lipid bimolecular membrane forms a lamellar layer on the skin, and suppressing effects on an increase in amount of combined water and evaporation of water are recognized in the lipid bimolecular membrane. As a result, xerotic symptoms of the skin can effectively be improved.

Description

【発明の詳細な説明】Detailed Description of the Invention

【0001】[0001]

【産業上の利用分野】本発明は、良好な保水性を有して
皮膚に水分を補給し、或いは皮膚からの水分蒸散を制御
することにより、皮膚を乾燥から保護して、皮膚水分の
減少に起因する皮膚症状の悪化又は疾患を防止或いは改
善し得る皮膚外用剤に関する。
BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention protects skin from dryness and reduces skin moisture by hydrating the skin with good water retention or controlling transpiration of water from the skin. The present invention relates to an external preparation for skin that can prevent or improve the deterioration of skin symptoms or diseases caused by.

【0002】[0002]

【従来の技術】皮膚の乾燥を防止し、皮膚水分量の減少
に起因する皮膚状態の悪化や皮膚疾患を防止或いは改善
するため、従来よりアミノ酸類や多価アルコール等の保
湿剤を配合し、皮膚上での水分保持能を高めた皮膚外用
剤や、エステル油,高級アルコール等のエモリエント剤
を配合して、皮膚上に油膜を形成して皮膚からの水分蒸
散を防ぐ皮膚外用剤等が提供されてきた。
2. Description of the Related Art In order to prevent the skin from drying and prevent or ameliorate the deterioration of the skin condition and the skin diseases caused by the decrease in the amount of water in the skin, moisturizers such as amino acids and polyhydric alcohols have been conventionally compounded. Provides a skin external preparation with improved water retention on the skin and an emollient such as ester oil and higher alcohol to form an oil film on the skin to prevent water evaporation from the skin. It has been.

【0003】また、近年皮膚最外層に存在する角質層の
構造と保湿機能が明らかになるにつれ、スフィンゴ脂質
やセラミド等、角質層に存在し皮膚からの水分蒸散を防
御する物質を配合することも検討されてきた。
In addition, as the structure and moisturizing function of the stratum corneum present in the outermost layer of the skin have become clear in recent years, substances such as sphingolipids and ceramides that are present in the stratum corneum and protect against water evaporation from the skin may be added. Has been considered.

【0004】さらに、保湿剤の経皮吸収を高めたり、皮
膚の水分保持機能を高める物質を皮膚内に浸透させるべ
く、これら物質をリポソームに内包して配合することも
提案されてきている。
Further, it has been proposed to incorporate these substances in liposomes in order to enhance the percutaneous absorption of the moisturizing agent and to permeate into the skin substances that enhance the water retention function of the skin.

【0005】しかし、通常用いられる保湿剤は吸湿性の
物質であり、これら自身の保水能力はあまり高くなく、
低湿度下では逆に皮膚から水分を吸い上げてしまって逆
効果となり、高湿度下では外気中の水分を吸収してべた
べたした不快な使用感を与えるという欠点があった。一
方、エモリエント剤を用いる場合には、十分な閉塞性を
得るため塗布量を多くするとべたつき感が顕著となり、
かといって使用量を少なくすると十分な閉塞性が得られ
ないという問題があった。
However, the commonly used moisturizers are hygroscopic substances, and their water retention capacity is not so high.
On the contrary, it has a drawback that it absorbs moisture from the skin under low humidity, which has the opposite effect, and absorbs moisture in the outside air under high humidity to give a sticky and unpleasant feeling. On the other hand, when an emollient is used, a sticky feeling becomes remarkable when the coating amount is increased to obtain sufficient occlusive property,
However, if the amount used is reduced, there is a problem that sufficient occlusion cannot be obtained.

【0006】また、スフィンゴ脂質等の細胞間脂質は優
れた閉塞効果を示すものの、他の油性基剤との相溶性が
悪く、安定な製剤が得にくいという問題があった。さら
に、皮膚上に塗布した場合、閉塞効果による皮膚からの
水分蒸散防御作用は期待できるが、角質細胞間に存在す
る状態での保水機能を期待することはできなかった。保
湿剤や活性成分をリポソームに内包して配合する技術に
ついても、製剤中リポソームが安定な状態で保持されに
くく、リポソームを皮膚上に適用したとしても、角質層
の有する保水機能及び水分蒸散防御機能を再現すること
は困難であった。
[0006] Although intercellular lipids such as sphingolipids have an excellent occluding effect, there is a problem that it is difficult to obtain a stable preparation because of poor compatibility with other oily bases. Furthermore, when it is applied on the skin, it can be expected to have a blocking effect on water evaporation from the skin, but it cannot be expected to have a water-retaining function in the state existing between corneocytes. Regarding the technology of encapsulating moisturizers and active ingredients in liposomes, it is difficult to keep the liposomes in a stable state in the formulation, and even if the liposomes are applied on the skin, the water-retaining function and water-transpiration prevention function of the stratum corneum Was difficult to reproduce.

【0007】[0007]

【発明が解決しようとする課題】本発明は、従来の保湿
を目的とする皮膚外用剤の有する上記したような問題点
を解決し、角質層の有する保水機能或いは水分蒸散防御
機能を、皮膚上においてほぼ完全に再現することのでき
る皮膚外用剤を提供し、皮膚の乾燥に起因する皮膚疾患
や皮膚状態の悪化を改善し、さらには防止することを目
的とする。
DISCLOSURE OF THE INVENTION The present invention solves the above-mentioned problems of the conventional external preparation for skin for the purpose of moisturizing, and provides the water retention function or the water evaporation protection function of the stratum corneum on the skin. The purpose of the present invention is to provide an external preparation for skin that can be almost completely reproduced, to improve and even prevent deterioration of skin diseases and skin conditions caused by dry skin.

【0008】[0008]

【課題を解決するための手段】上記の課題を解決する目
的で、本発明者らは脂質二分子膜にアミノ酸,高級脂肪
酸及び高級アルコールから選ばれる1種以上を含有させ
て複合化することにより、脂質二分子膜より成るラメラ
構造を皮膚上で形成させた場合、皮膚からの水分蒸散を
抑制することができ、さらには結合水量が上昇すること
を見い出し、すでに開示している(特願平6−1023
31)。今回、アミノ酸の中で特にプロリン,ロイシ
ン,イソロイシンより選ばれる1種又は2種以上と、水
溶性高分子の1種又は2種以上とを組み合わせて脂質二
分子膜に複合化することにより、水分保持機能が大幅に
向上することを見い出し、本発明を完成するに至った。
For the purpose of solving the above-mentioned problems, the present inventors have prepared a lipid bilayer by incorporating at least one selected from amino acids, higher fatty acids and higher alcohols into a complex. It was found that when a lamellar structure composed of a lipid bilayer is formed on the skin, water evaporation from the skin can be suppressed and the amount of bound water increases, which has already been disclosed (Patent application No. 6-1023
31). This time, by combining one or more kinds selected from proline, leucine, and isoleucine among amino acids with one or more kinds of water-soluble polymers to form a complex with a lipid bilayer membrane, It was found that the holding function was significantly improved, and the present invention was completed.

【0009】脂質二分子膜は、ホスファチジルコリン,
ホスファチジルエタノールアミン,ホスファチジルセリ
ン,ホスファチジルイノシトール等のグリセロリン脂
質、スフィンゴミエリン等のスフィンゴリン脂質、グル
コシルアシルグリセロール等のグリセロ糖脂質、ホスフ
ァチジルグルコシルアシルグリセロール等のホスホグリ
セロ糖脂質、グルコセレブロシド,ガラクトセレブロシ
ド等のスフィンゴ糖脂質を用いて調製することができ
る。かかる脂質を80〜90℃に攪拌しながら加温溶解
し、プロリン,ロイシン或いはイソロイシンと水溶性高
分子の溶液を添加して含有させる。添加量はプロリン,
ロイシン,イソロイシンの1種又は2種以上については
総量で脂質二分子膜複合体の1〜20重量%、水溶性高
分子については総量で脂質二分子膜複合体の0.05〜
1.0重量%程度が適当である。前記配合量より少ない
と十分な保水機能或いは水分蒸散防御機能を発揮させる
ことができず、逆に前記配合量を超えると製剤の安定性
や皮膚外用剤の使用感に影響を与える。
The lipid bilayer is composed of phosphatidylcholine,
Glycerophospholipids such as phosphatidylethanolamine, phosphatidylserine, and phosphatidylinositol, sphingolipids such as sphingomyelin, glyceroglycolipids such as glucosylacylglycerol, phosphoglyceroglycolipids such as phosphatidylglucosylacylglycerol, sphingosugars such as glucocerebrosides, and galactocerebrosides. It can be prepared using lipids. The lipid is dissolved by heating at 80 to 90 ° C. with stirring, and a solution of proline, leucine or isoleucine and a water-soluble polymer is added and contained. The added amount is proline,
For leucine and isoleucine, one or two or more of them are contained in a total amount of 1 to 20% by weight of the lipid bilayer membrane complex, and for water-soluble polymers, the total amount is 0.05 to 0.05 of the lipid bilayer membrane complex.
About 1.0% by weight is suitable. If the amount is less than the above amount, a sufficient water retention function or water evaporation prevention function cannot be exhibited, and conversely, if the amount exceeds the above amount, the stability of the preparation and the feeling of use of the external preparation for skin are affected.

【0010】プロリン,ロイシン或いはイソロイシンと
しては、通常天然に存在するL-体の他、D-体又はDL-ラ
セミ体を用いることができる。水溶性高分子としては、
ヒドロキシル基やカルボキシル基といった陰イオン性の
官能基を有するものが本発明の目的に適しており、特に
ポリアクリル酸及びその塩,カルボキシビニルポリマー
及びその塩,ヒドロキシエチルセルロース,カルボキシ
メチルセルロース及びその塩,ヒアルロン酸及びその塩
が好ましく、これらより1種又は2種以上を組み合わせ
て配合する。
As the proline, leucine or isoleucine, the naturally occurring L-form, D-form or DL-racemic form can be used. As water-soluble polymer,
Those having an anionic functional group such as a hydroxyl group or a carboxyl group are suitable for the purpose of the present invention, and particularly polyacrylic acid and its salts, carboxyvinyl polymer and its salts, hydroxyethyl cellulose, carboxymethyl cellulose and its salts, hyalurone. Acids and salts thereof are preferable, and one kind or a combination of two or more kinds is mixed from these.

【0011】従って、本発明においては、脂質二分子膜
にプロリン,ロイシン及びイソロイシンの1種又は2種
以上と、水溶性高分子の1種又は2種以上とを組み合わ
せて含有させ、複合化したものを皮膚外用剤基剤に配合
する。かかる複合化脂質二分子膜は、外用剤基剤中に配
合した時多重膜の層状(ラメラ)構造をとって安定に存
在し得る。また複合化脂質二分子膜は球状のリポソーム
として配合することもできる。
Therefore, in the present invention, the lipid bilayer is combined with one or more kinds of proline, leucine and isoleucine and one or more kinds of water-soluble polymer to form a complex. The product is incorporated into a skin external preparation base. Such a complex lipid bilayer membrane can stably exist by taking a layered (lamellar) structure of a multi-layer membrane when blended in a base for external preparation. The complex lipid bilayer membrane can also be blended as spherical liposomes.

【0012】[0012]

【作用】本発明で皮膚外用剤に配合する複合化脂質二分
子膜の水分保持機能について、以下に示す。すなわち、
L-プロリン15重量%及びL-イソロイシン10重量%を
含有する水素添加大豆リン脂質の脂質二分子膜30重量
%に対し、表1に示す水溶性高分子の1重量%水溶液を
25重量%加えて複合化し、これを精製水で100重量
%として試料とした。但し、ポリアクリル酸ナトリウム
については0.25重量%水溶液を25重量%添加し
た。これら試料50mgをメンブランフィルターに塗布
して水を入れたバイアルビン上に置き、メンブランフィ
ルターに含有される水分量を、経時的に近赤外水分計に
より測定した。その際対照として、水溶性高分子を添加
していないL-プロリン,L-イソロイシン複合化脂質二分
子膜を用いた。測定は5回行い、各試料及び対照につい
ての平均値を図1に示した。
[Function] The water-retaining function of the complex lipid bilayer membrane compounded in the external preparation for skin according to the present invention is shown below. That is,
To hydrogenated soybean phospholipid containing 30% by weight of hydrogenated soybean phospholipid containing 15% by weight of L-proline and 10% by weight of L-isoleucine, 25% by weight of 1% by weight aqueous solution of the water-soluble polymer shown in Table 1 was added. Was made into a composite, and this was made 100% by weight with purified water to obtain a sample. However, with respect to sodium polyacrylate, 25% by weight of a 0.25% by weight aqueous solution was added. 50 mg of these samples were applied to a membrane filter and placed on a vial containing water, and the amount of water contained in the membrane filter was measured with a near infrared moisture meter over time. At that time, as a control, an L-proline, L-isoleucine complexed lipid bilayer membrane to which a water-soluble polymer was not added was used. The measurement was performed 5 times, and the average value for each sample and control is shown in FIG.

【表1】 [Table 1]

【0013】図1より、脂質二分子膜にL-プロリン及び
L-イソロイシンに加えて水溶性高分子を添加して複合化
することにより、L-プロリン及びL-イソロイシンを複合
化しただけの対照に比べて経時的な水分の減少が少なく
なっており、水分保持機能が上昇していることが認めら
れる。
From FIG. 1, it can be seen that L-proline and
By adding a water-soluble polymer in addition to L-isoleucine to form a complex, the decrease in water content over time is less than that of a control in which L-proline and L-isoleucine are simply combined. It is recognized that the retention function is increased.

【0014】続いて、上記試料及び対照の複合化脂質二
分子膜において、精製水で希釈しない状態で含有する結
合水量を、示差走査型熱量計を用いて自由水の融解エン
タルピーを測定することにより求めた。結果を図2に示
す。
Subsequently, in the complex lipid bilayer membranes of the above-mentioned sample and control, the amount of bound water contained in a state not diluted with purified water was measured by measuring the enthalpy of fusion of free water using a differential scanning calorimeter. I asked. The results are shown in Figure 2.

【0015】図2において、水溶性高分子としてポリア
クリル酸ナトリウム及びカルボキシビニルポリマーを用
いた複合化脂質二分子膜(1及び2)では、対照(6)
に比べて結合水量が大幅に上昇していた。ヒドロキシエ
チルセルロース,カルボキシメチルセルロース及びヒア
ルロン酸を複合化した脂質二分子膜(3,4及び5)に
ついても、わずかではあるが結合水量の増加が認められ
ている。従って、図1に示した複合化脂質二分子膜の水
分保持機能の上昇は、結合水量の増加も一因であること
が示唆される。
In FIG. 2, in the complex lipid bilayer membrane (1 and 2) using sodium polyacrylate and carboxyvinyl polymer as the water-soluble polymer, the control (6)
The amount of bound water was significantly higher than that of. Also in the lipid bilayer membranes (3, 4 and 5) in which hydroxyethyl cellulose, carboxymethyl cellulose and hyaluronic acid are complexed, a slight increase in the amount of bound water was observed. Therefore, it is suggested that the increase in the water retention function of the complex lipid bilayer membrane shown in FIG. 1 is also due to the increase in the amount of bound water.

【0016】そして、本発明に係る皮膚外用剤を皮膚片
に薄く塗布し偏光顕微鏡で観察すると、脂質二分子膜よ
り成るラメラ層の形成が認められる。従って、本発明に
係る皮膚外用剤を皮膚上に塗布した場合、皮膚上で複合
化脂質二分子膜のラメラ層が形成され、これが皮膚を覆
い、水分の蒸散を抑制するとともに、良好な保水機能を
発揮し、皮膚に必要な水分を補給して乾燥から防ぐ作用
を示すものと考えられる。
When the external preparation for skin according to the present invention is thinly applied to a skin piece and observed with a polarizing microscope, the formation of a lamella layer composed of a lipid bilayer membrane is recognized. Therefore, when the external preparation for skin according to the present invention is applied on the skin, a lamella layer of the complex lipid bilayer is formed on the skin, which covers the skin and suppresses the evaporation of water, and has a good water retention function. It is considered that it exerts the action of supplying the necessary moisture to the skin to prevent it from drying out.

【0017】[0017]

【実施例】さらに本発明について、実施例により詳細に
説明する。実施例1〜実施例3は本発明に係る皮膚用ク
リームである。これらの処方を以下に示す。各実施例に
おいて複合化脂質二分子膜としては、表2中の調製例
1,調製例2及び調製例3の組成のものを用いた。これ
ら脂質二分子膜は、クリーム基剤中において層状のラメ
ラ構造体をとって分散して存在していた。
EXAMPLES The present invention will be described in more detail with reference to Examples. Examples 1 to 3 are skin creams according to the present invention. These formulations are shown below. As the complex lipid bilayer membrane in each example, those having the compositions of Preparation Example 1, Preparation Example 2 and Preparation Example 3 in Table 2 were used. These lipid bilayers were dispersed in the cream base in a layered lamella structure.

【0018】 皮膚用クリーム (1)ステアリン酸 1.00 (重量%) (2)ステアリルアルコール 4.00 (3)モノステアリン酸グリセリン 3.00 (4)硬化ヒマシ油 7.00 (5)スクワラン 10.00 (6)サフラワー油 2.00 (7)セスキオレイン酸ソルビタン 1.00 (8)水酸化ナトリウム 0.05 (9)プルラン 0.10 (10)パラオキシ安息香酸メチル 0.10 (11)精製水 66.25 (12)複合化脂質二分子膜 5.00 (13)香料 0.50 (1)〜(7)を75℃に加熱溶解し、これに75℃に加熱溶
解した(8)〜(11)を加えて乳化し、冷却して40℃にて
(12),(13)を添加し、さらに室温まで冷却して調製す
る。ここで(12)の複合化脂質二分子膜の替わりに、水素
添加大豆レシチンのみで調製したリポソームを配合した
ものを比較例1、L-プロリン15重量%及びL-イソロイ
シン10重量%を複合化した脂質二分子膜を用いたもの
を比較例2とした。
Skin cream (1) Stearic acid 1.00 (% by weight) (2) Stearyl alcohol 4.00 (3) Glycerin monostearate 3.00 (4) Hydrogenated castor oil 7.00 (5) Squalane 10 0.000 (6) Safflower oil 2.00 (7) Sorbitan sesquioleate 1.00 (8) Sodium hydroxide 0.05 (9) Pullulan 0.10 (10) Methyl paraoxybenzoate 0.10 (11) Purified water 66.25 (12) Complex lipid bilayer 5.00 (13) Perfume 0.50 (1) to (7) were heated and dissolved at 75 ° C., and then dissolved at 75 ° C. (8) ~ (11) is added to emulsify, cool and at 40 ℃
(12) and (13) are added, and further cooled to room temperature to prepare. Here, in place of the complex lipid bilayer membrane of (12), a liposome prepared by only hydrogenated soybean lecithin was compounded with Comparative Example 1, L-proline 15% by weight and L-isoleucine 10% by weight. What used the said lipid bilayer membrane was made into the comparative example 2.

【0019】実施例4〜実施例7は、本発明に係る皮膚
用乳液である。これらの処方を以下に示す。各実施例に
は、表2中の調製例4,調製例5,調製例6及び調製例
7の組成のものをリポソーム化して用いた。
Examples 4 to 7 are skin emulsions according to the present invention. These formulations are shown below. In each Example, the compositions of Preparation Example 4, Preparation Example 5, Preparation Example 6 and Preparation Example 7 in Table 2 were used as liposomes.

【0020】 皮膚用乳液 (1)ステアリン酸 0.50 (重量%) (2)セタノール 1.50 (3)モノステアリン酸グリセリン 2.00 (4)スクワラン 5.00 (5)ホホバ油 1.00 (6)セスキオレイン酸ソルビタン 0.50 (7)1,3-ブチレングリコール 5.00 (8)水酸化ナトリウム 0.02 (9)パラオキシ安息香酸メチル 0.10 (10)精製水 81.28 (11)複合化脂質二分子膜 3.00 (12)香料 0.10 (1)〜(6)を75℃に加熱溶解し、これに75℃に加熱溶
解した(7)〜(10)を添加して乳化し、冷却後40℃にて
(11),(12)を添加し、さらに室温まで冷却して調製す
る。ここで(11)の複合化脂質二分子膜の替わりに、水素
添加大豆レシチンのみで調製したリポソームを配合した
ものを比較例3、L-プロリン15重量%及びL-イソロイ
シン10重量%を複合化した脂質二分子膜を用いたもの
を比較例4とした。
Emulsion for skin (1) Stearic acid 0.50 (% by weight) (2) Cetanol 1.50 (3) Glycerin monostearate 2.00 (4) Squalane 5.00 (5) Jojoba oil 1.00 (6) Sorbitan sesquioleate 0.50 (7) 1,3-butylene glycol 5.00 (8) Sodium hydroxide 0.02 (9) Methyl paraoxybenzoate 0.10 (10) Purified water 81.28 ( 11) Complex lipid bilayer 3.00 (12) Perfume 0.10 (1) to (6) were heated and dissolved at 75 ° C, and (7) to (10) which was heated and dissolved at 75 ° C were added thereto. Emulsify and cool at 40 ° C
(11) and (12) are added, and further cooled to room temperature to prepare. Here, in place of the complex lipid bilayer membrane of (11), a liposome prepared only with hydrogenated soybean lecithin was compounded with Comparative Example 3, 15% by weight of L-proline and 10% by weight of L-isoleucine. What used the said lipid bilayer membrane was made into the comparative example 4.

【0021】実施例8〜実施例10は、本発明に係る皮
膚用化粧水である。これらの処方を以下に示す。各実施
例には、表2中の調製例8,調製例9,調製例10の組
成のものをリポソーム化して用いた。
Examples 8 to 10 are skin lotions according to the present invention. These formulations are shown below. In each example, the compositions of Preparation Example 8, Preparation Example 9 and Preparation Example 10 in Table 2 were used in the form of liposomes.

【0022】 皮膚用化粧水 (1)ポリオキシエチレン(20)ソルビタン 1.0 (重量%) モノラウレート (2)1,3-ブチレングリコール 3.0 (3)ソルビトール 2.0 (4)エタノール 5.0 (5)複合化脂質二分子膜 2.0 (6)パラオキシ安息香酸メチル 0.1 (7)キサンタンガム1.0重量%水溶液 10.0 (8)香料 0.2 (9)精製水 76.7 (5)以外の全成分を混合,溶解して均一とし、次いで(5)
を分散させて調製する。ここで(5)の複合化脂質二分子
膜の替わりに、水素添加大豆レシチンのみで調製したリ
ポソームを配合したものを比較例5、L-プロリン15重
量%及びL-イソロイシン10重量%を複合化した脂質二
分子膜を用いたものを比較例6とした。
Skin lotion (1) Polyoxyethylene (20) sorbitan 1.0 (wt%) monolaurate (2) 1,3-butylene glycol 3.0 (3) sorbitol 2.0 (4) ethanol 5.0 (5) Complex lipid bilayer 2.0 (6) Methyl paraoxybenzoate 0.1 (7) Xanthan gum 1.0 wt% aqueous solution 10.0 (8) Perfume 0.2 (9) Purified water 76.7 Mix all components except (5), dissolve to homogeneity, then (5)
Are prepared by dispersing. Here, in place of the complex lipid bilayer membrane of (5), a liposome prepared only with hydrogenated soybean lecithin was compounded with Comparative Example 5, L-proline 15% by weight and L-isoleucine 10% by weight. What used the said lipid bilayer membrane was made into the comparative example 6.

【表2】 [Table 2]

【0023】上記の実施例及び比較例について、ヒトに
よる使用試験を行った。皮膚の乾燥に起因する重篤な皮
膚症状を認める患者20名を1群とし、各群について実
施例及び比較例の各試料をそれぞれブラインドで4週間
継続使用させ、皮膚症状の改善状況を観察した。皮膚症
状は、皮膚の乾燥,ひび割れ,落屑,しわの発生状況を
目視で判断し、重症度の場合を4点、中症度の場合を3
点、軽症度の場合を2点、わずかに認められる程度の場
合を1点、症状の認められない場合を0点として評価
し、20名の平均値を算出した。結果は使用前の皮膚状
態の評価と併せて表3〜表5に示した。また、各群にお
ける紅斑及び腫脹の発生状況についても同時に観察し
た。
Human use tests were conducted on the above-mentioned Examples and Comparative Examples. 20 patients with serious skin symptoms caused by dry skin were set as one group, and each sample of Example and Comparative Example was continuously used in blind for 4 weeks, and the improvement status of skin symptoms was observed. . For skin symptoms, the appearance of dryness, cracks, desquamation, and wrinkles of the skin is visually judged, and 4 points in the case of severity and 3 points in the case of moderate degree.
An average value of 20 subjects was calculated by scoring points, 2 points for mildness, 1 point for slightly observed symptoms, and 0 point for no symptoms. The results are shown in Tables 3 to 5 together with the evaluation of the skin condition before use. The occurrence of erythema and swelling in each group was also observed at the same time.

【0024】表3において、比較例1のクリームを使用
した群でも皮膚の乾燥症状の改善が見られるが、それで
も軽症度〜中程度の症状が認められる。比較例2のクリ
ームを使用した群ではさらに改善が見られるが、それで
も明確に症状が認められ、特に「しわ」に関しては、ほ
ぼ軽症度にまで改善された程度にとどまっていた。これ
に対し、実施例使用群では全症状において全快したパネ
ラーも存在し、全快しなくても症状はわずかに認められ
る程度であった。
In Table 3, even in the group using the cream of Comparative Example 1, dry skin symptoms were improved, but still mild to moderate symptoms were observed. Further improvement was observed in the group using the cream of Comparative Example 2, but the symptoms were still clearly observed, and in particular, regarding “wrinkles”, the degree was improved to almost mild degree. On the other hand, in the group used in the Examples, there were some panelists who recovered from all symptoms, and even if they did not recover, the symptoms were slightly observed.

【表3】 [Table 3]

【0025】表4においても、実施例使用群の乾燥症状
改善効果は大きく、総合所見で重症度に近い症状であっ
た患者のほとんどが、全快或いはわずかに症状を認める
程度に回復している。比較例3使用群において総合所見
で症状が中症度程度まで軽減されたに過ぎないのと対照
的であった。比較例4使用群においても、乾燥症状はほ
ぼ軽症度にまで改善されていたが、実施例使用群に認め
られる程度には至らなかった。
Also in Table 4, the effect of improving the dry symptom of the group used in the Examples is large, and most of the patients who have symptoms close to the severity of the overall findings have recovered to the level of complete or slight symptom. This was in contrast to the comparative example 3 in which the symptoms were alleviated to a moderate degree in the overall findings. In the group used in Comparative Example 4 as well, the dry symptom was improved to almost a mild degree, but it was not as high as that observed in the group used in Example.

【表4】 [Table 4]

【0026】表5においては、試料が化粧水の形態をと
っているので、皮膚に対する閉塞効果が小さく、比較例
5使用群では中症度程度にまで症状の軽減が認められる
に過ぎない。比較例6使用群においても、軽症度程度ま
で改善は見られているが、実施例使用群においては、乾
燥症状がわずかに認められる程度にまで軽減,改善され
ており、化粧水の剤型でありながら十分な改善効果が得
られることが示された。
In Table 5, since the sample is in the form of a lotion, the effect of blocking the skin is small, and in the group of Comparative Example 5 used, the symptom is only reduced to a moderate degree. In the group used in Comparative Example 6 as well, an improvement was seen to a degree of mildness, but in the group used in Example, it was reduced and improved to such an extent that a dry symptom was slightly observed. It has been shown that a sufficient improvement effect can be obtained.

【表5】 [Table 5]

【0027】また、上記のいずれの実施例及び比較例使
用群においても、特に紅斑,腫脹の発生は認められなか
った。
In addition, no erythema or swelling was observed in any of the groups used in the above Examples and Comparative Examples.

【0028】また、いずれの実施例においても、複合化
脂質二分子膜より成る層状ラメラ構造体及びリポソーム
は、皮膚外用剤基剤中で3ヶ月間以上安定に保持されて
いた。そして、皮膚片上に塗布した場合に、比較的安定
なラメラ状の脂質二分子膜を形成することが確認され
た。
In each of the examples, the lamellar lamellar structure composed of the complex lipid bilayer and the liposome were stably retained for 3 months or longer in the skin external preparation base. It was confirmed that when applied on a piece of skin, a relatively stable lamellar lipid bilayer membrane was formed.

【0029】[0029]

【発明の効果】以上詳述したように、本発明による皮膚
外用剤を使用することによって、皮膚上に保水機能及び
閉塞機能を有する脂質二分子膜のラメラ層を形成させる
ことができ、かかるラメラ層が角質層中に存在する細胞
間脂質と同様の生理作用を発揮して、皮膚を乾燥から有
効に保護することが可能となった。その結果、ひび割
れ,落屑,しわ等乾燥に起因する皮膚の諸症状を改善
し、老人性乾皮症等乾燥に起因する皮膚疾患を有効に治
療し、さらにはかかる症状や疾患を有効に予防すること
ができた。さらに、本発明にかかる皮膚外用剤は、製剤
安定性も良好で、紅斑や腫脹の発生など皮膚刺激性や感
作性も認められず、安全性上も問題のないものであっ
た。
As described above in detail, by using the external preparation for skin according to the present invention, it is possible to form a lamellar layer of a lipid bilayer having a water retaining function and an occluding function on the skin. The layer exerted the same physiological action as the intercellular lipids present in the stratum corneum, and it became possible to effectively protect the skin from dryness. As a result, it improves various skin symptoms caused by dryness such as cracks, desquamation, and wrinkles, effectively treats skin diseases caused by dryness such as senile xerosis, and effectively prevents such symptoms and diseases. I was able to. Further, the external preparation for skin according to the present invention had good formulation stability, no skin irritation or sensitization such as erythema or swelling was observed, and there was no problem in safety.

【図面の簡単な説明】[Brief description of drawings]

【図1】本発明で用いる複合化脂質二分子膜(表1の試
料1〜試料5)の水分保持機能を、L-プロリン及びL-イ
ソロイシンを複合化し、水溶性高分子を複合化しない脂
質二分子膜を対照して示す図である。
FIG. 1 is a lipid complexing L-proline and L-isoleucine, which does not complex a water-soluble polymer, with the water-retaining function of the complex lipid bilayer membrane (Sample 1 to Sample 5 in Table 1) used in the present invention. It is a figure which contrasts and shows a bilayer membrane.

【図2】本発明で用いる複合化脂質二分子膜(表1の試
料1〜試料5)の結合水量を、L-プロリン及びL-イソロ
イシンを複合化し、水溶性高分子を複合化しない脂質二
分子膜を対照して示す図である。
FIG. 2 shows the amount of bound water of a complex lipid bilayer membrane (Sample 1 to Sample 5 in Table 1) used in the present invention, which is obtained by complexing L-proline and L-isoleucine and not complexing a water-soluble polymer. It is a figure which contrasts and shows a molecular film.

【符号の説明】[Explanation of symbols]

1 試料1の複合化脂質二分子膜 2 試料2の複合化脂質二分子膜 3 試料3の複合化脂質二分子膜 4 試料4の複合化脂質二分子膜 5 試料5の複合化脂質二分子膜 6 対照の複合化脂質二分子膜 1 Complexed Lipid Bilayer of Sample 1 2 Complexed Lipid Bilayer of Sample 2 3 Complexed Lipid Bilayer of Sample 3 4 Complexed Lipid Bilayer of Sample 4 5 Complexed Lipid Bilayer of Sample 5 6 Controlled complex lipid bilayer

フロントページの続き (51)Int.Cl.6 識別記号 庁内整理番号 FI 技術表示箇所 A61K 9/127 D Continuation of the front page (51) Int.Cl. 6 Identification number Office reference number FI technical display area A61K 9/127 D

Claims (4)

【特許請求の範囲】[Claims] 【請求項1】 プロリン,ロイシン及びイソロイシンよ
り選ばれる1種又は2種以上と、水溶性高分子の1種又
は2種以上とを含有する脂質二分子膜を配合することを
特徴とする、皮膚外用剤。
1. A skin comprising a lipid bilayer membrane containing one or more selected from proline, leucine and isoleucine and one or more kinds of water-soluble polymers. Topical agent.
【請求項2】 水溶性高分子が、ポリアクリル酸及びそ
の塩,カルボキシビニルポリマー及びその塩,ヒドロキ
シエチルセルロース,カルボキシメチルセルロース及び
その塩,ヒアルロン酸及びその塩より成る群から選ばれ
ることを特徴とする、請求項1に記載の皮膚外用剤。
2. The water-soluble polymer is selected from the group consisting of polyacrylic acid and salts thereof, carboxyvinyl polymer and salts thereof, hydroxyethyl cellulose, carboxymethyl cellulose and salts thereof, hyaluronic acid and salts thereof. The external preparation for skin according to claim 1.
【請求項3】 脂質二分子膜が多重膜層状(ラメラ)構
造をとることを特徴とする、請求項1又は請求項2に記
載の皮膚外用剤。
3. The external preparation for skin according to claim 1, wherein the lipid bilayer has a multilamellar structure (lamella).
【請求項4】 皮膚外用剤が化粧料であることを特徴と
する、請求項1ないし請求項3に記載の皮膚外用剤。
4. The external preparation for skin according to any one of claims 1 to 3, wherein the external preparation for skin is a cosmetic.
JP3933895A 1995-02-03 1995-02-03 Dermal preparation for external use Pending JPH08208423A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP3933895A JPH08208423A (en) 1995-02-03 1995-02-03 Dermal preparation for external use

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP3933895A JPH08208423A (en) 1995-02-03 1995-02-03 Dermal preparation for external use

Publications (1)

Publication Number Publication Date
JPH08208423A true JPH08208423A (en) 1996-08-13

Family

ID=12550310

Family Applications (1)

Application Number Title Priority Date Filing Date
JP3933895A Pending JPH08208423A (en) 1995-02-03 1995-02-03 Dermal preparation for external use

Country Status (1)

Country Link
JP (1) JPH08208423A (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000513706A (en) * 1995-11-03 2000-10-17 オキュラー・リサーチ・オブ・ボストン インコーポレイテッド Skin care formulations and methods
WO2001013888A1 (en) * 1998-08-20 2001-03-01 Shionogi & Co., Ltd. Liposome preparations for external use
JPWO2004009041A1 (en) * 2002-07-22 2005-12-08 辻製油株式会社 Skin cosmetic composition
JP2008266324A (en) * 2007-03-29 2008-11-06 Kose Corp Liposome composition and external preparation for skin containing liposome composition
JP2011133417A (en) * 2009-12-25 2011-07-07 Lvmc Inc Simple screening method of antioxidation substance for skin cosmetics using sensor for active oxygen species concentration measurement

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000513706A (en) * 1995-11-03 2000-10-17 オキュラー・リサーチ・オブ・ボストン インコーポレイテッド Skin care formulations and methods
WO2001013888A1 (en) * 1998-08-20 2001-03-01 Shionogi & Co., Ltd. Liposome preparations for external use
JPWO2004009041A1 (en) * 2002-07-22 2005-12-08 辻製油株式会社 Skin cosmetic composition
JP2008266324A (en) * 2007-03-29 2008-11-06 Kose Corp Liposome composition and external preparation for skin containing liposome composition
JP2011133417A (en) * 2009-12-25 2011-07-07 Lvmc Inc Simple screening method of antioxidation substance for skin cosmetics using sensor for active oxygen species concentration measurement

Similar Documents

Publication Publication Date Title
JP3609834B2 (en) Skin preparation
JP2866114B2 (en) Cosmetics
JP2001503069A (en) Non-inflammatory cosmetic and pharmaceutical compositions
JP6377381B2 (en) Liposome composition
US11826468B2 (en) Insoluble active substance carrier comprising transfersome
JP2606761B2 (en) Moisturizer
WO2018020903A1 (en) External agent for skin
KR100715311B1 (en) A cosmeticss to promote the transepidermal absorption and stabilize ursolic acid for anti-wrinkle and its manufacturing method thereof
JPH08208423A (en) Dermal preparation for external use
JPH08183726A (en) Skin preparation for external use
JP2008247786A (en) External preparation for skin
JPH07285827A (en) External preparation for skin
JPH09291013A (en) Skin cosmetic material
JP2003095844A (en) Cosmetic
JP3766070B2 (en) Water resistant O / W cosmetics with UV protection effect
JPH0672841A (en) Gel-like massage agent and pack agent
JP7298863B2 (en) emulsified cosmetic
JP3506627B2 (en) Chitosan derivative, external skin preparation containing the chitosan derivative and cosmetic
JP3527053B2 (en) Cosmetics
JP3326059B2 (en) Skin cosmetics
JP5756602B2 (en) Cosmetic base comprising liposome modified with gelatin and / or elastin-constituting polypeptide and skin cosmetic containing the same
JP3001121B2 (en) External preparation for skin
JPH02101008A (en) Skin cosmetic
JPS62413A (en) Cosmetic
KR102015890B1 (en) Polysaccharide liquid crystal composition and manufacturing method thereof and cosmetic composition comprising the same